Magnitude and predictors of first-line antiretroviral therapy regimen change among HIV infected adults: A retrospective cross sectional study.
Adult HIV patients
Ethiopia
HAART change
Predictors
Prevalence
Reasons
Journal
Annals of medicine and surgery (2012)
ISSN: 2049-0801
Titre abrégé: Ann Med Surg (Lond)
Pays: England
ID NLM: 101616869
Informations de publication
Date de publication:
Sep 2022
Sep 2022
Historique:
received:
06
06
2022
revised:
25
07
2022
accepted:
26
07
2022
entrez:
23
9
2022
pubmed:
24
9
2022
medline:
24
9
2022
Statut:
epublish
Résumé
Regimen change remains a significant challenge towards the achievement of human immunodeficiency virus (HIV) treatment success. In developing countries where limited treatment options are available, strategies are required to ensure the sustainability and durability of the starting regimens. Nevertheless, information regarding the rate and predictors of regimen change is limited in these settings. This study was undertaken to determine the prevalence and predictors of changes in ART regimens among patients initiating highly active antiretroviral therapy (HAART) at XX. An institutional based retrospective cross-sectional study was conducted among adult naïve HIV patients who had initiated HAART at XX between 2010. Data were extracted by reviewing their medical charts using a pretested structured check-list. The Kaplan-Meier survival analyses were used to describe the probability of ARV regimen changes while Cox proportional hazard regression models were employed to identify the predictors of ARV regimen modifications. Data were analyzed using SPSS version 21 software, and statistical significant was deemed at p < 0.05. A total of 770 patients were enrolled in this study of these 165 (21.43%) had their ART regimen modified at least once. Drug toxicity was the main reason for regimen change followed by TB comorbidity, and treatment failure. Positive baseline TB symptoms (aHR = 1.63, p = 0.037), and Zidovudine based regimen (aHR = 1.76, p = 0.011) as compared to Stavudine based regimen were at higher risk of ART modification. Conversely, urban residence, baseline World Health organization (WHO) stage 2 as compared to WHO stage 1, baseline CD4 count ≥301 as compared to CD4 count ≤200 were at lower risk of ART modification. The rate of initial HAART regimen change was found to be high. Thus, less toxic and better tolerated HIV treatment options should be available and used more frequently. Moreover, early detection and initiation of ART by the government is highly demanded to maximize the benefit and reduce risk of ART modifications.
Sections du résumé
Background
UNASSIGNED
Regimen change remains a significant challenge towards the achievement of human immunodeficiency virus (HIV) treatment success. In developing countries where limited treatment options are available, strategies are required to ensure the sustainability and durability of the starting regimens. Nevertheless, information regarding the rate and predictors of regimen change is limited in these settings.
Objective
UNASSIGNED
This study was undertaken to determine the prevalence and predictors of changes in ART regimens among patients initiating highly active antiretroviral therapy (HAART) at XX.
Materials and methods
UNASSIGNED
An institutional based retrospective cross-sectional study was conducted among adult naïve HIV patients who had initiated HAART at XX between 2010. Data were extracted by reviewing their medical charts using a pretested structured check-list. The Kaplan-Meier survival analyses were used to describe the probability of ARV regimen changes while Cox proportional hazard regression models were employed to identify the predictors of ARV regimen modifications. Data were analyzed using SPSS version 21 software, and statistical significant was deemed at p < 0.05.
Results
UNASSIGNED
A total of 770 patients were enrolled in this study of these 165 (21.43%) had their ART regimen modified at least once. Drug toxicity was the main reason for regimen change followed by TB comorbidity, and treatment failure. Positive baseline TB symptoms (aHR = 1.63, p = 0.037), and Zidovudine based regimen (aHR = 1.76, p = 0.011) as compared to Stavudine based regimen were at higher risk of ART modification. Conversely, urban residence, baseline World Health organization (WHO) stage 2 as compared to WHO stage 1, baseline CD4 count ≥301 as compared to CD4 count ≤200 were at lower risk of ART modification.
Conclusion
UNASSIGNED
The rate of initial HAART regimen change was found to be high. Thus, less toxic and better tolerated HIV treatment options should be available and used more frequently. Moreover, early detection and initiation of ART by the government is highly demanded to maximize the benefit and reduce risk of ART modifications.
Identifiants
pubmed: 36147157
doi: 10.1016/j.amsu.2022.104303
pii: S2049-0801(22)01063-9
pmc: PMC9486446
doi:
Types de publication
Journal Article
Langues
eng
Pagination
104303Informations de copyright
© 2022 Published by Elsevier Ltd on behalf of IJS Publishing Group Ltd.
Références
HIV Med. 2010 Feb;11(2):104-13
pubmed: 19732176
Tanzan J Health Res. 2013 Jan;15(1):11-8
pubmed: 26591668
BMC Pharmacol Toxicol. 2014 Jun 23;15:32
pubmed: 24957052
Trop Med Int Health. 2008 Mar;13(3):328-33
pubmed: 18298607
HIV Med. 2006 Apr;7(3):156-62
pubmed: 16494629
Curr Opin HIV AIDS. 2013 Nov;8(6):528-34
pubmed: 24100873
J Int AIDS Soc. 2016 Jul 15;19(1):21133
pubmed: 27424601
J Assoc Physicians India. 2009 May;57:384-8
pubmed: 19634284
Int J Surg. 2021 Dec;96:106165
pubmed: 34774726
J Acquir Immune Defic Syndr (1988). 1994 Oct;7(10):1095-8
pubmed: 7916052
J Acquir Immune Defic Syndr. 2003 Dec 1;34(4):407-14
pubmed: 14615659
J Acquir Immune Defic Syndr. 2007 Jul 1;45(3):304-10
pubmed: 17414931
PLoS One. 2010 Jun 01;5(6):e10490
pubmed: 20531956
Lancet HIV. 2016 Aug;3(8):e361-e387
pubmed: 27470028
BMC Pharmacol Toxicol. 2018 Jun 5;19(1):28
pubmed: 29871665
AIDS. 1998 Dec 3;12(17):2313-20
pubmed: 9863874
Open AIDS J. 2018 Mar 12;12:11-19
pubmed: 29576815
PLoS One. 2016 Oct 7;11(10):e0164299
pubmed: 27716827
AIDS Res Ther. 2016 Feb 17;13:10
pubmed: 26889204
BMJ Open. 2018 Apr 5;8(4):e019181
pubmed: 29626042
Curr Opin HIV AIDS. 2008 May;3(3):306-12
pubmed: 19372983
N Am J Med Sci. 2012 Jan;4(1):19-23
pubmed: 22393543
AIDS. 2007 Jun 19;21(10):1301-8
pubmed: 17545706
AIDS Res Hum Retroviruses. 2007 Jun;23(6):794-800
pubmed: 17604542
BMC Pharmacol Toxicol. 2019 Nov 1;20(1):63
pubmed: 31675986
AIDS. 2013 Mar 13;27(5):833-4
pubmed: 23719352
PLoS One. 2016 Aug 10;11(8):e0159994
pubmed: 27509182
J Acquir Immune Defic Syndr. 2008 Feb 1;47(2):206-11
pubmed: 17971717
J Int AIDS Soc. 2014 Nov 02;17(4 Suppl 3):19768
pubmed: 25397512
PLoS One. 2014 Apr 02;9(4):e93106
pubmed: 24695108
BMC Res Notes. 2018 Jun 5;11(1):351
pubmed: 29871671
Clin Infect Dis. 2002 Jan 15;34(2):239-47
pubmed: 11740714